{
  "symbol": "SILO",
  "company_name": "Silo Pharma Inc",
  "ir_website": "https://ir.silopharma.com/",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management",
          "url": "https://ir.silopharma.com/news-releases/",
          "content": "[ ![Silo Pharma](/assets/uploads/2024/02/silo-pharma-logo_outlined-01.png) ](https://ir.silopharma.com/)\n\nSelect Page\n\n  * [Home](https://silopharma.com/)\n  * [Pipeline](https://silopharma.com/our-pipeline-and-ip/)\n  * [About Us](https://silopharma.com/about/)\n  * [Investors](https://ir.silopharma.com/)\n  * [Contact Us](https://silopharma.com/contact-us/)\n\n\n\nInvestor relations\n\n  * [Overview](https://ir.silopharma.com/)\n  * [News](#)\n    * [Events](https://ir.silopharma.com/events/)\n    * [Press Releases](https://ir.silopharma.com/news-releases/)\n  * [Stock Info](https://ir.silopharma.com/stock-information/)\n  * [SEC Filings](https://ir.silopharma.com/sec-filings/)\n  * [Governance](#)\n    * [Board of Directors](https://ir.silopharma.com/board-of-directors/)\n    * [Our Team](https://ir.silopharma.com/our-team/)\n    * [Corporate Governance Documents](https://ir.silopharma.com/corporate-governance/)\n    * [Board Diversity Matrix](https://ir.silopharma.com/assets/uploads/2023/09/SILO-Board-Diversity-Matrix.pdf)\n  * [Scientific Advisory Board](https://ir.silopharma.com/scientific-advisory-board/)\n  * [FAQs](https://ir.silopharma.com/faqs/)\n  * [Email Alerts](https://ir.silopharma.com/investor-email-alerts/)\n\n\n\n# News Releases\n\n#### IR Contact\n\nInvestor Relations 560 Sylvan Ave Suite 3160 Englewood Cliffs, NJ 07632\n\nEmail: **investors@silopharma.com**\n\nData delayed 15 minutes unless otherwise indicated (view [delay times](//www.quotemedia.com/legal/tos/#times) for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. [Terms of Use](//www.quotemedia.com/legal/tos/).\n\nCorporate Governance \n\n### **Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.**\n\nShareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com. \n\nReports may be made anonymously or confidentially.\n\n× \n\nDisclaimer \n\nYou are about to review presentations, reports and/or filings of Silo Pharma, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Silo Pharma, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Silo Pharma, Inc. \n\n[I Accept](https://ir.silopharma.com/assets/uploads/2024/09/SILO-FINAL-presentation_9.4.24.pdf) [I Decline](/)\n\n× \n\nsilopharma.com\n\nWe value your privacy.\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clikcing \"Accept All\", you consent to our use of cookies.\n\nNecessaryAccept All\n\n1 month6 months12 months\n\nHighest level of privacy. Data accessed for necessary basic operations only. Data shared with 3rd parties to ensure the site is secure and works on your device\n\nBalanced experience. Data accessed for content personalisation and site optimisation. Data shared with 3rd parties may be used to track you and store your preferences for this site.\n\nHighest level of personalisation. Data accessed to make ads and media more relevant. Data shared with 3rd parties may be use to track you on this site and other sites you visit. \n\nConsent Preferences\n\nUse the toggles below to specify your data sharing purposes for this website.\n\nBasic Operations\n\nThis type of sharing is necessary for us to access the data we need to make sure the website is secure and working properly.\n\nData Accessed:\n\n  * Anonymous data like browser name and version\n  * Pseudonymous data like authentication token\n\n\n\nContent Personalization\n\nWhen enabled, you allow us to save your preferences and create a profile about you so we can deliver personalized content.\n\nData Accessed:\n\n  * Anonymous data like device type, model and operating system\n  * Pseudonymous data like site browsing preferences\n  * Personal data like your IP address and location\n\n\n\nSite Optimization\n\nWhen enabled, you allow us to monitor your behavior so we can analyze and improve the services on our website for all visitors.\n\nData Accessed:\n\n  * Anonymous data like the address of the previously visited website (HTTP Referer)\n  * Pseudonymous data like website activity identifiers\n  * Personal data like content, search and purchase history\n\n\n\nAd Personalization\n\nWhen enabled, you allow us access to share data with our advertising partners that build profiles about you across multiple websites.\n\nData Accessed:\n\n  * Anonymous data like affiliate referral links\n  * Pseudonymous data like identifiers used to track and profile users\n  * Personal data like your age, gender and demographics\n\n\n\nProtection & Metrics\n\nView your consent record, and the list of 3rd parties blocked and allowed based on your settings. \n\nConsent Metrics\n\nConsent ID| —  \n---|---  \nDate of Consent| —  \nData Access Level| —  \nPurpose Categories| —  \nDuration of Consent| —  \n  \nPrivacy Protection\n\nServices Blocked\n\n  * Google Fonts\n\n\n\nServices Allowed\n\n  * Google Analytics\n\n\n\nSave my preferences\n\n  * Customize\n\n\n"
        },
        {
          "title": "Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders",
          "url": "https://ir.silopharma.com/news-releases/",
          "content": "[ ![Silo Pharma](/assets/uploads/2024/02/silo-pharma-logo_outlined-01.png) ](https://ir.silopharma.com/)\n\nSelect Page\n\n  * [Home](https://silopharma.com/)\n  * [Pipeline](https://silopharma.com/our-pipeline-and-ip/)\n  * [About Us](https://silopharma.com/about/)\n  * [Investors](https://ir.silopharma.com/)\n  * [Contact Us](https://silopharma.com/contact-us/)\n\n\n\nInvestor relations\n\n  * [Overview](https://ir.silopharma.com/)\n  * [News](#)\n    * [Events](https://ir.silopharma.com/events/)\n    * [Press Releases](https://ir.silopharma.com/news-releases/)\n  * [Stock Info](https://ir.silopharma.com/stock-information/)\n  * [SEC Filings](https://ir.silopharma.com/sec-filings/)\n  * [Governance](#)\n    * [Board of Directors](https://ir.silopharma.com/board-of-directors/)\n    * [Our Team](https://ir.silopharma.com/our-team/)\n    * [Corporate Governance Documents](https://ir.silopharma.com/corporate-governance/)\n    * [Board Diversity Matrix](https://ir.silopharma.com/assets/uploads/2023/09/SILO-Board-Diversity-Matrix.pdf)\n  * [Scientific Advisory Board](https://ir.silopharma.com/scientific-advisory-board/)\n  * [FAQs](https://ir.silopharma.com/faqs/)\n  * [Email Alerts](https://ir.silopharma.com/investor-email-alerts/)\n\n\n\n# News Releases\n\n#### IR Contact\n\nInvestor Relations 560 Sylvan Ave Suite 3160 Englewood Cliffs, NJ 07632\n\nEmail: **investors@silopharma.com**\n\nData delayed 15 minutes unless otherwise indicated (view [delay times](//www.quotemedia.com/legal/tos/#times) for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. [Terms of Use](//www.quotemedia.com/legal/tos/).\n\nCorporate Governance \n\n### **Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.**\n\nShareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com. \n\nReports may be made anonymously or confidentially.\n\n× \n\nDisclaimer \n\nYou are about to review presentations, reports and/or filings of Silo Pharma, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Silo Pharma, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Silo Pharma, Inc. \n\n[I Accept](https://ir.silopharma.com/assets/uploads/2024/09/SILO-FINAL-presentation_9.4.24.pdf) [I Decline](/)\n\n× \n\nsilopharma.com\n\nWe value your privacy.\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clikcing \"Accept All\", you consent to our use of cookies.\n\nNecessaryAccept All\n\n1 month6 months12 months\n\nHighest level of privacy. Data accessed for necessary basic operations only. Data shared with 3rd parties to ensure the site is secure and works on your device\n\nBalanced experience. Data accessed for content personalisation and site optimisation. Data shared with 3rd parties may be used to track you and store your preferences for this site.\n\nHighest level of personalisation. Data accessed to make ads and media more relevant. Data shared with 3rd parties may be use to track you on this site and other sites you visit. \n\nConsent Preferences\n\nUse the toggles below to specify your data sharing purposes for this website.\n\nBasic Operations\n\nThis type of sharing is necessary for us to access the data we need to make sure the website is secure and working properly.\n\nData Accessed:\n\n  * Anonymous data like browser name and version\n  * Pseudonymous data like authentication token\n\n\n\nContent Personalization\n\nWhen enabled, you allow us to save your preferences and create a profile about you so we can deliver personalized content.\n\nData Accessed:\n\n  * Anonymous data like device type, model and operating system\n  * Pseudonymous data like site browsing preferences\n  * Personal data like your IP address and location\n\n\n\nSite Optimization\n\nWhen enabled, you allow us to monitor your behavior so we can analyze and improve the services on our website for all visitors.\n\nData Accessed:\n\n  * Anonymous data like the address of the previously visited website (HTTP Referer)\n  * Pseudonymous data like website activity identifiers\n  * Personal data like content, search and purchase history\n\n\n\nAd Personalization\n\nWhen enabled, you allow us access to share data with our advertising partners that build profiles about you across multiple websites.\n\nData Accessed:\n\n  * Anonymous data like affiliate referral links\n  * Pseudonymous data like identifiers used to track and profile users\n  * Personal data like your age, gender and demographics\n\n\n\nProtection & Metrics\n\nView your consent record, and the list of 3rd parties blocked and allowed based on your settings. \n\nConsent Metrics\n\nConsent ID| —  \n---|---  \nDate of Consent| —  \nData Access Level| —  \nPurpose Categories| —  \nDuration of Consent| —  \n  \nPrivacy Protection\n\nServices Blocked\n\n  * Google Fonts\n  * Google Tag Manager\n\n\n\nServices Allowed\n\n  * —\n\n\n\nSave my preferences\n\n  * Customize\n\n\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Latest presentation",
          "url": "https://ir.silopharma.com/assets/uploads/2024/09/SILO-presentation_9.4.24_FINAL.pdf",
          "content": "Error extracting PDF content: Exceeded 30 redirects."
        },
        {
          "title": "Investor Fact Sheet",
          "url": "https://ir.silopharma.com/assets/uploads/2024/09/SILO_Fact-Sheet_8.22.24_FINAL.pdf",
          "content": "FACT SHEET\nSEPTEMBER 2024\nNasdaq: SILO\nsilopharma.com\nNovel therapies for the underserved.\nSilo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel\ntherapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain\nconditions, and central nervous system (CNS) diseases. Through the acquisition and licensing of technology rights\nand IP from leading universities and researchers, Silo focuses on developing traditional therapies and psychedelic\ntreatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is a nose-to-\nbrain intranasal formulation targeting PTSD and stress-induced anxiety disorders. A pre-investigational New Drug\nApplication (pre-IND) for SPC-15 was submitted to the FDA in June 2024. The next drug in development is SP-26,\na time release ketamine-loaded implant for fibromyalgia and chronic pain relief. Two preclinical programs are\nunderway for neurological diseases: SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD),\nand SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Columbia University has granted Silo exclusive\nworldwide rights to further develop, manufacture, and commercialize SPC-15 and SPC-14. Silo intends to utilize the\nFDA’s streamlined 505(b)(2) pathway for SPC-15 and SP-26, which would shorten clinical timelines and reduce drug\ndevelopment costs.\nInvestment Highlights\nClear timeline to first-in-human clinical trials for lead asset SPC-15 pending FDA guidance on pre-IND.\nGLP study underway.\nExclusive global licenses granted by Columbia University to further develop, manufacture, and\ncommercialize SPC-15 and SPC-14 worldwide.\nStreamlined 505(b)(2) regulatory pathway for drug approval planned for top two priority drug candidates.\nDiversified pipeline of novel IP-protected technologies and assets showing promise in underserved rare\ndisease, neurological, and mental health indications.\nDisruptive market potential in central nervous system therapeutics industry; projected CAGR of 8% for\nCNS drugs during the period 2022 (~$110.4 B) to 2032 (~$238.8 B)1.\nAssets well-protected by strong IP, with 10 issued and/or provisional patents.\nAmple capital resources to support upcoming catalysts, prudent use of capital for drug development, and\nzero debt.\nLeadership with expertise in drug development and licensing, asset acquisition, biotech management,\ncapital markets, and finance.\n1 Global Market Insights, Central Nervous System Therapeutics Market Size, June 2023\nDevelopment Timeline\nHigh Value Collaborations and Assets\nFour novel drug candidates target three health areas: mental health, chronic pain, and neurology.\n2 World Health Organization, May 2024\n3 Market.Us., Global Alzheimer’s Disease Therapeutics Market report, January 2024\nRecent Announcements\nAugust 14, 2024 — Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic\nAugust 7, 2024 — Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide\nJuly 22, 2024 — Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules\nJuly 18, 2024 — Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15\nJuly 16, 2024 — Silo Pharma Secures Exclusive Global License for Alzheimer’s Therapeutic\nJuly 8, 2024 — Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety\nJune 26, 2024 — Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety\nJune 7, 2024 — Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia\nJune 4, 2024 — Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety\nLeadership\nEric Weisblum, Founder and CEO\n20 years of investing, building, and managing businesses, including in-licensing and developing therapeutic assets. Formerly\nPresident of Sableridge Capital and board member of Nasdaq-listed Aikido Pharma.\nDaniel Ryweck CPA, CFO\nMill City Ventures III Ltd, Sun BioPharma, Inc., Dala Petroleum Corp.\nJames Kuo, M.D., MBA, Vice President of R&D\nAthena Bioventures, ImmunoPrecise Antibodies, Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, Discovery\nLaboratories, HealthCare Ventures\nCharles B. Nemeroff, M.D., Ph.D., Scientific Advisor\nUniversity of Texas, University of Texas at Austin’s Dell Medical School\nMarket Snapshot\nShare Price 52-Wk. Range Avg. Vol. Shares O/S Market Cap\n$1.40 (8/21/24) $0.84 - $4.50 5.2M 4.5M $6.2M\nPrice and volume quotes from Yahoo! Finance\nAnalyst Coverage\nLaidlaw & Company. Yale Jen\nSilo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236\nInvestor Relations Contact: 800-705-0120 | investors@silopharma.com\nForward-Looking Statements: This fact sheet contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995.\nThese statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended\nto identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the\nCompany”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions,\ndifficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other\nfactors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will\nprove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this fact sheet, whether as a result of new\ninformation, future events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events except as required by law."
        },
        {
          "title": "Investor Presentation",
          "url": "https://ir.silopharma.com/assets/uploads/2024/09/SILO-FINAL-presentation_9.4.24.pdf",
          "content": "NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS\nInvestor Presentation\nSeptember 2024\nNasdaq:\nSILO\nFORWARD-LOOKING STATEMENTS\nThis presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the\nPrivate Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar\nexpressions that are intended to identify forward-looking statements. Such statements involve known and unknown\nrisks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the\nCompany”) to differ materially from the results expressed or implied by such statements, including changes to\nanticipated sources of revenues, future economic and competitive conditions, difficulties in developing the\nCompany’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer\nspending on the Company’s products and other factors. Accordingly, although the Company believes that the\nexpectations reflected in such forward-looking statements are reasonable, there can be no assurance that such\nexpectations will prove to be correct. The Company disclaims any obligations to publicly update or release any\nrevisions to the forward-looking information contained in this presentation, whether as a result of new information,\nfuture events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events\nexcept as required by law.\n2\nNasdaq:\nSILO\nNovel Therapeutics for Post-traumatic stress disorder (PTSD)\nUNMET MEDICAL NEEDS\nStress-induced psychiatric disorders\nFibromyalgia and chronic pain disorders\nWe are a developmental stage\nCentral nervous system (CNS) diseases\nbiopharmaceutical company\nOur focus is on developing\ndeveloping novel therapeutics\ntraditional therapies and psychedelic\nthat address underserved\ntreatments in novel formulations and\nconditions. drug delivery systems.\n3\nMultiple Levers for\nNasdaq:\nVALUE CREATION\nSILO\nClear timeline to first-in-human clinical trials for lead asset SPC-15\n•\nfollowing FDA guidance on pre-IND.\nExclusive global licenses granted by Columbia University for two portfolio\n•\nassets.\nStreamlined 505(b)(2) regulatory pathway for drug approval planned for\n•\npriority drug candidates.\nDiversified pipeline of novel IP-protected technologies and assets.\n•\nMarket potential in central nervous system therapeutics industry.\n•\nAssets well-protected by strong intellectual property portfolio.\n•\nSufficient capital resources to support upcoming catalysts.\n•\nAccomplished leadership with broad expertise in life sciences.\n•\n4\nUnder-Addressed\nNasdaq:\nMEDICAL NEEDS\nSILO\nMental Health Neurology Chronic Pain\nSPC-15 | Intranasal PTSD treatment SPC-14 | Alzheimer’s Disease SP-26 | Non-opioid pain solution\n• Selective intranasal drug • Potential to improve and restore • Ketamine-based therapeutic\ncompound (non-psychedelic) cognitive and memory function implant targeting fibromyalgia\n• Patented nose-to-brain delivery • Self-administered treatment\nbypasses blood-brain barrier\nSPU-16 | CNS homing peptide • Safely regulated dosage and\n• Direct, heightened drug time release\n• Directly targets damaged tissue\nconcentration in the brain\nand inflammation in spinal cord\n• Optimized patient safety and\ntherapeutic delivery\n5\nNasdaq:\nSILO\nSilo Pharma’s\nDRUG PIPELINE\nOur current assets have shown\npromise in a range of diseases\nand conditions including PTSD,\nchronic pain, Alzheimer’s\nDisease, and multiple sclerosis.\n6\nSPC-15:\nNasdaq:\nPROPHYLACTIC TREATMENT FOR PTSD\nSILO\nBlood Brain Barrier\nDrug:\n• Novel seIroNtoninT 4 (R5-HTO4) reDceptUor agConiTst thIaOt utiliNzes biomarkers for\ntreatment\nStage:\nLorem ipsum dolor sit amet, consectetur adipiscing elit,\n• Pre-IND submitted for first-in-human trials\nsed do eiusmod tempor incididunt ut labore et dolore\nmagna aliqua. Ut enim ad minim veniam, quis nostrud\nUnmet need:\nexercitation ullamco laboris nisi ut aliquip ex ea\n• No new cdormugm aopdop rcoovnaslesq fuoart .P DTuSisD a iunt en ieruarrely d 2ol5o ry iena rs1\n• Affects eresptirmehaetnedde r3it. 9in% v ooluf pwtaotrel dv’esli tp eospseu lcailtluiomn 1d olore eu\n• Cumulaftuivgeia pt nreuvllaa lpeanrciaetu irn. Eyxocuepntge upre soinptl eo cdcoaeucbalte cdu pfridoamta t2 017 to 2022 to\n7.5%1\nnon proident, sunt in culpa qui officia deserunt mollit\nanim id est laborum.\nCompetitive advantages:\n• Patented, cutting-edge intranasal nose-to-brain drug dispersion\n• Nose-to-brain method increases drug’s concentration in the brain\n• Faster onset of therapeutic benefit and optimized safety\nRoute of nose to brain delivery\n1 FT Specialist, Endpoints in Focus, Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote. June 2024.\n7\nSPC-26:\nNasdaq:\nKETAMINE IMPLANT FOR FIBROMYALGIA\nSILO\nDrug:\n• Subcutaneous time-released ketamine-based injectable dissolvable\nimplant\nStage:\n• Preclinical research\nUnmet need:\n• Only FDA-approved drugs for fibromyalgia are 2 antidepressants and 1 anti-\nseizure medicine1\n• Chronic pain treatment market projected growth to $106.3B in 2028 at\n7.9% CAGR2\n• Global fibromyalgia treatment market projected growth to $4.1B in 2032 at\n4.3% CAGR3\nCompetitive advantages:\n• Innovative non-opioidchronic pain therapeutic\n• Implant method designed to safely regulate dosage and time release\n• Attractive alternative to intravenous delivery\n1 WebMD, Fibromyalgia: Treatment and Medications. February 2024.\n2 Business Research Company, Chronic Pain Market Growth Analysis With Investment Opportunities For 2024-2033. July 2024. 8\n3 Precedence Research, Fibromyalgia Treatment Market Size to Worth USD 4.13 Billion by 2032. June 2024.\nNasdaq:\nSILO\nNEUROLOGY PROGRAMS\nS P C - 1 4 : A L Z H E I M E R ’ S D I S E A S E S P U - 1 6 : M U L T I P L E S C L E R O S I S\nDrug: Drug:\n• Novel drug targeting two receptor molecules • Central nervous system homing peptide\nStage: Stage:\n• Preclinical research • Preclinical research\nUnmet need: Unmet need:\n• Treatment market projected growth to $30.8Bin 2033, at • Global MS drugs market size projected growth to $38.9B\n18.8%CAGR1\nby 2032, at a 7.9% CAGR2\nCompetitive advantages:\nCompetitive advantages:\n• Has shown efficacy against luteinizing hormone (LH) in\n• Novel homing peptides reduce toxicity and advance\nattenuating learned helplessness, preservative behavior,\npayload of therapeutic\nand hyponeophagia (a measure of anxiety)\n2 Fortune Business Insights, Multiple Sclerosis Drugs Market Size, Share & Industry Analysis… July\n1 Market.us, Alzheimer’s Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 |\n2024.\nDriven by the Advancements in Neurological Research. January 2024.\n9\nNasdaq:\nSILO\nTIMELINE\nJANUARY FEBRUARY MARCH APRIL\nLorem ipsum dolor sit amet, Lorem ipsum dolor sit amet, Lorem ipsum dolor sit amet, Lorem ipsum dolor sit amet,\nconsectetur adipiscing elit, sed consectetur adipiscing elit, sed consectetur adipiscing elit, sed consectetur adipiscing elit, sed\ndo eiusmod tempor incididunt ut do eiusmod tempor incididunt ut do eiusmod tempor incididunt ut do eiusmod tempor incididunt ut\nlabore et dolore magna aliqua. labore et dolore magna aliqua. labore et dolore magna aliqua. labore et dolore magna aliqua.\nUt enim ad minim veniam, quis Ut enim ad minim veniam, quis Ut enim ad minim veniam, quis Ut enim ad minim veniam, quis\nnostrud exercitation ullamco nostrud exercitation ullamco nostrud exercitation ullamco nostrud exercitation ullamco\nlaboris nisi ut aliquip ex ea laboris nisi ut aliquip ex ea laboris nisi ut aliquip ex ea laboris nisi ut aliquip ex ea\ncommodo consequat. commodo consequat. commodo consequat. commodo consequat.\n10\nNasdaq:\nSILO\nCreating\nVALUE\nOur strategic business platform\nsupports our ongoing\ndevelopment of novel drugs\nwith the potential to transform\npatient care.\n11\nFDA’s 505(b)(2)\nNasdaq:\nSILO\nABBREVIATED REGULATORY PATHWAY\nSilo Pharma intends to utilize the FDA’s streamlined 505(b)(2) pathway for its top\ntwo priority drug candidates, SPC-15 and SP-26.\nSection 505(b)(2) of the Federal Food, Drug, and Cosmetics Act (FDCA)\n• Streamlined pathway to New Drug Application (NDA) approval for novel\nrepurposed drugs\n• NDA relies upon publicly available data on active ingredient\n• Can significantly shorten clinical timelines and reduce drug development\ncosts\n12\nMANAGEMENT\nNasdaq:\nSILO\nEric Weisblum CEO\n◉ 20+ years investing, building and managing businesses\n◉ Prior president of Sableridge Capital\n◉ Former board member of Aikido Pharma., a Nasdaq-listed biotech company focused on the\ncommercialization of oncology therapeutics\nDaniel Ryweck CFO\n◉ Certified Public Accountant\n◉ Formerly chief compliance officer of Mill City Ventures III Ltd, interim chief financial officer\nof Sun BioPharma, Inc., and director of Dala Petroleum Corp.\nKEY PERSONNEL\nJames Kuo, M.D., MBA Vice President of R&D\n◉ Current managing director of Athena Bioventures\n◉ Formerly held executive positions in private and listed bioscience companies in the U.S.,\nCanada, and Europe\n◉ Chairman of the Board of ImmunoPrecise Antibodies and board director of Tryp Therapeutics\n◉ Former CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery\nLaboratories\n13\nNasdaq:\nSILO\nSCIENTIFIC ADVISORY\n◉ Chair, Department of Psychiatry and Behavioral\nIn addition to our work with world-\nSciences, Dell Medical School, University of\nrenowned educational institutions, Texas at Austin; director, Institute for Early Life\nwe engaged a scientific advisory Adversity Research, Department of Psychiatry\nand Behavioral Sciences, Mulva Clinic for the\nchair for guidance regarding\nNeurosciences\npotential acquisitions and product\n◉ University of North Carolina (UNC) School of\ndevelopment.\nMedicine, Duke University\n◉ Brain and Behavior Research Foundation;\nAnxiety and Depression Association of America\nCharles B. Nemeroff M.D., Ph.D.\n(ADAA); National Academy of Medicine\n14\nBOARD OF DIRECTORS\nNasdaq:\nSILO\nEric Weisblum CEO Wayne Linsley Director\n◉ 20+ years investing, building and managing ◉ 40 years in business management\nbusinesses ◉ Wide and varied skillset including sales and sales\n◉ Prior president of Sableridge Capital management, finance (public and private\n◉ Former board member of Aikido Pharma, a companies), accounting, audit support and financial\nNasdaq-listed biotech company focused on the reporting\ncommercialization of oncology therapeutics ◉ Independent director for Hoth Therapeutics Inc.\n(NASDAQ: HOTH) and DatChat Inc. (NASDAQ:\nDATS)\nKevin Muñoz M.D. Director Jeff Pavell D.O. Director\n◉ Director of Operations at Physical ◉ Site proctor for Rusk Institute residents training for\nMedicine and Rehabilitation Rehabilitation Medicine and Chief of\n◉ Former researcher with Harlem Health Rehabilitation Medicine at Englewood Hospital\nPromotion Center in New York and Medical Center in New Jersey\n◉ Doctor of Medicine from Xavier University ◉ Residency and chief residency at New York\nSchool of Medicine, B.S. from University of University Medical Center’s Rusk Institute of\nMichigan with distinction Rehabilitation and Bellevue Hospital, respectively,\nNew York College of Osteopathic Medicine with\nhonors\n15\nKey Collaborations and\nNasdaq:\nSILO\nINTELLECTUAL PROPERTY\nExclusive collaborations with prominent medical research partners CRO & Manufacturing\nprovide valuable IP, assets, and time-to-market advantages.\nPartners include…\nColumbia University\n• Exclusive worldwide rights to develop, manufacture, and commercialize\nSPC-15 and SPC-14\n• Extensive issued and pending IP patent applications acquired with license\nagreement\nUniversity of Maryland, Baltimore\n• Exclusive, worldwide, sublicensable, royalty-bearing Master License\nAgreement\n• Rights to central nervous system-homing peptides for investigation and\ntreatment of multiple sclerosis and other neuroinflammatory pathology\n16\nCreating\nNasdaq:\nVALUE SILO\nSPC-15 SP-26 502(b)(2) Exclusivity\nPathway to Non-opioid Streamlined pathway Strong asset\nfirst-in-human pain relief to FDA approval protection\ntrials\nMarket Size Partners Credentials Capital\nLarge CNS Prominent Broad life sciences Sufficient\nmarkets collaborations expertise resources, no debt\n17\nNasdaq: SILO\nThank you.\nSilo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236\nInvestor Relations Contact: 800-705-0120 | investors@silopharma.com\n18"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.silopharma.com/sec-filings/",
          "content": "[ ![Silo Pharma](/assets/uploads/2024/02/silo-pharma-logo_outlined-01.png) ](https://ir.silopharma.com/)\n\nSelect Page\n\n  * [Home](https://silopharma.com/)\n  * [Pipeline](https://silopharma.com/our-pipeline-and-ip/)\n  * [About Us](https://silopharma.com/about/)\n  * [Investors](https://ir.silopharma.com/)\n  * [Contact Us](https://silopharma.com/contact-us/)\n\n\n\nInvestor relations\n\n  * [Overview](https://ir.silopharma.com/)\n  * [News](#)\n    * [Events](https://ir.silopharma.com/events/)\n    * [Press Releases](https://ir.silopharma.com/news-releases/)\n  * [Stock Info](https://ir.silopharma.com/stock-information/)\n  * [SEC Filings](https://ir.silopharma.com/sec-filings/)\n  * [Governance](#)\n    * [Board of Directors](https://ir.silopharma.com/board-of-directors/)\n    * [Our Team](https://ir.silopharma.com/our-team/)\n    * [Corporate Governance Documents](https://ir.silopharma.com/corporate-governance/)\n    * [Board Diversity Matrix](https://ir.silopharma.com/assets/uploads/2023/09/SILO-Board-Diversity-Matrix.pdf)\n  * [Scientific Advisory Board](https://ir.silopharma.com/scientific-advisory-board/)\n  * [FAQs](https://ir.silopharma.com/faqs/)\n  * [Email Alerts](https://ir.silopharma.com/investor-email-alerts/)\n\n\n\n# SEC Filings\n\nData delayed 15 minutes unless otherwise indicated (view [delay times](//www.quotemedia.com/legal/tos/#times) for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. [Terms of Use](//www.quotemedia.com/legal/tos/).\n\nCorporate Governance \n\n### **Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.**\n\nShareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com. \n\nReports may be made anonymously or confidentially.\n\n× \n\nDisclaimer \n\nYou are about to review presentations, reports and/or filings of Silo Pharma, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Silo Pharma, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Silo Pharma, Inc. \n\n[I Accept](https://ir.silopharma.com/assets/uploads/2024/09/SILO-FINAL-presentation_9.4.24.pdf) [I Decline](/)\n\n× \n\nsilopharma.com\n\nWe value your privacy.\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clikcing \"Accept All\", you consent to our use of cookies.\n\nNecessaryAccept All\n\n1 month6 months12 months\n\nHighest level of privacy. Data accessed for necessary basic operations only. Data shared with 3rd parties to ensure the site is secure and works on your device\n\nBalanced experience. Data accessed for content personalisation and site optimisation. Data shared with 3rd parties may be used to track you and store your preferences for this site.\n\nHighest level of personalisation. Data accessed to make ads and media more relevant. Data shared with 3rd parties may be use to track you on this site and other sites you visit. \n\nConsent Preferences\n\nUse the toggles below to specify your data sharing purposes for this website.\n\nBasic Operations\n\nThis type of sharing is necessary for us to access the data we need to make sure the website is secure and working properly.\n\nData Accessed:\n\n  * Anonymous data like browser name and version\n  * Pseudonymous data like authentication token\n\n\n\nContent Personalization\n\nWhen enabled, you allow us to save your preferences and create a profile about you so we can deliver personalized content.\n\nData Accessed:\n\n  * Anonymous data like device type, model and operating system\n  * Pseudonymous data like site browsing preferences\n  * Personal data like your IP address and location\n\n\n\nSite Optimization\n\nWhen enabled, you allow us to monitor your behavior so we can analyze and improve the services on our website for all visitors.\n\nData Accessed:\n\n  * Anonymous data like the address of the previously visited website (HTTP Referer)\n  * Pseudonymous data like website activity identifiers\n  * Personal data like content, search and purchase history\n\n\n\nAd Personalization\n\nWhen enabled, you allow us access to share data with our advertising partners that build profiles about you across multiple websites.\n\nData Accessed:\n\n  * Anonymous data like affiliate referral links\n  * Pseudonymous data like identifiers used to track and profile users\n  * Personal data like your age, gender and demographics\n\n\n\nProtection & Metrics\n\nView your consent record, and the list of 3rd parties blocked and allowed based on your settings. \n\nConsent Metrics\n\nConsent ID| —  \n---|---  \nDate of Consent| —  \nData Access Level| —  \nPurpose Categories| —  \nDuration of Consent| —  \n  \nPrivacy Protection\n\nServices Blocked\n\n  * Google Fonts\n\n\n\nServices Allowed\n\n  * Google Analytics\n\n\n\nSave my preferences\n\n  * Customize\n\n\n"
        }
      ]
    },
    {
      "section_name": "Stock Info",
      "links": [
        {
          "title": "Stock Information",
          "url": "https://ir.silopharma.com/stock-information/",
          "content": "[ ![Silo Pharma](/assets/uploads/2024/02/silo-pharma-logo_outlined-01.png) ](https://ir.silopharma.com/)\n\nSelect Page\n\n  * [Home](https://silopharma.com/)\n  * [Pipeline](https://silopharma.com/our-pipeline-and-ip/)\n  * [About Us](https://silopharma.com/about/)\n  * [Investors](https://ir.silopharma.com/)\n  * [Contact Us](https://silopharma.com/contact-us/)\n\n\n\nInvestor relations\n\n  * [Overview](https://ir.silopharma.com/)\n  * [News](#)\n    * [Events](https://ir.silopharma.com/events/)\n    * [Press Releases](https://ir.silopharma.com/news-releases/)\n  * [Stock Info](https://ir.silopharma.com/stock-information/)\n  * [SEC Filings](https://ir.silopharma.com/sec-filings/)\n  * [Governance](#)\n    * [Board of Directors](https://ir.silopharma.com/board-of-directors/)\n    * [Our Team](https://ir.silopharma.com/our-team/)\n    * [Corporate Governance Documents](https://ir.silopharma.com/corporate-governance/)\n    * [Board Diversity Matrix](https://ir.silopharma.com/assets/uploads/2023/09/SILO-Board-Diversity-Matrix.pdf)\n  * [Scientific Advisory Board](https://ir.silopharma.com/scientific-advisory-board/)\n  * [FAQs](https://ir.silopharma.com/faqs/)\n  * [Email Alerts](https://ir.silopharma.com/investor-email-alerts/)\n\n\n\n# Stock Information\n\nData delayed 15 minutes unless otherwise indicated (view [delay times](//www.quotemedia.com/legal/tos/#times) for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. [Terms of Use](//www.quotemedia.com/legal/tos/).\n\nCorporate Governance \n\n### **Reports Regarding LMP Automotive Holdings’ Accounting or Auditing Matters or Other Concerns and Communications with the Board of Directors.**\n\nShareholders and interested parties may communicate directly with the Board of Directors, the Audit Committee of the Board of Directors with respect to accounting issues, questionable accounting or auditing matters or internal accounting controls, any other Board committee, any individual Director, any group of Directors or the Lead Independent Director by e-mailing businessethics@lmpah.com. \n\nReports may be made anonymously or confidentially.\n\n× \n\nDisclaimer \n\nYou are about to review presentations, reports and/or filings of Silo Pharma, Inc. , that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Silo Pharma, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Silo Pharma, Inc. \n\n[I Accept](https://ir.silopharma.com/assets/uploads/2024/09/SILO-FINAL-presentation_9.4.24.pdf) [I Decline](/)\n\n× \n\nsilopharma.com\n\nWe value your privacy.\n\nWe use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clikcing \"Accept All\", you consent to our use of cookies.\n\nNecessaryAccept All\n\n1 month6 months12 months\n\nHighest level of privacy. Data accessed for necessary basic operations only. Data shared with 3rd parties to ensure the site is secure and works on your device\n\nBalanced experience. Data accessed for content personalisation and site optimisation. Data shared with 3rd parties may be used to track you and store your preferences for this site.\n\nHighest level of personalisation. Data accessed to make ads and media more relevant. Data shared with 3rd parties may be use to track you on this site and other sites you visit. \n\nConsent Preferences\n\nUse the toggles below to specify your data sharing purposes for this website.\n\nBasic Operations\n\nThis type of sharing is necessary for us to access the data we need to make sure the website is secure and working properly.\n\nData Accessed:\n\n  * Anonymous data like browser name and version\n  * Pseudonymous data like authentication token\n\n\n\nContent Personalization\n\nWhen enabled, you allow us to save your preferences and create a profile about you so we can deliver personalized content.\n\nData Accessed:\n\n  * Anonymous data like device type, model and operating system\n  * Pseudonymous data like site browsing preferences\n  * Personal data like your IP address and location\n\n\n\nSite Optimization\n\nWhen enabled, you allow us to monitor your behavior so we can analyze and improve the services on our website for all visitors.\n\nData Accessed:\n\n  * Anonymous data like the address of the previously visited website (HTTP Referer)\n  * Pseudonymous data like website activity identifiers\n  * Personal data like content, search and purchase history\n\n\n\nAd Personalization\n\nWhen enabled, you allow us access to share data with our advertising partners that build profiles about you across multiple websites.\n\nData Accessed:\n\n  * Anonymous data like affiliate referral links\n  * Pseudonymous data like identifiers used to track and profile users\n  * Personal data like your age, gender and demographics\n\n\n\nProtection & Metrics\n\nView your consent record, and the list of 3rd parties blocked and allowed based on your settings. \n\nConsent Metrics\n\nConsent ID| —  \n---|---  \nDate of Consent| —  \nData Access Level| —  \nPurpose Categories| —  \nDuration of Consent| —  \n  \nPrivacy Protection\n\nServices Blocked\n\n  * Google Fonts\n\n\n\nServices Allowed\n\n  * Google Analytics\n\n\n\nSave my preferences\n\n  * Customize\n\n\n"
        }
      ]
    }
  ]
}